A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.

PHASE2CompletedINTERVENTIONAL
Enrollment

753

Participants

Timeline

Start Date

March 18, 2011

Primary Completion Date

October 8, 2012

Study Completion Date

February 19, 2013

Conditions
Meningococcal VaccinerLP2086RepevaxN Meningitidis Serogroup BMeningitis
Interventions
BIOLOGICAL

rLP2086

0.5 mL dose, given at 0, 2 and 6 months.

BIOLOGICAL

Repevax

0.5 mL dose, given at 0 months.

BIOLOGICAL

Saline

0.5 mL dose, given at 0, 2 and 6 months.

BIOLOGICAL

Repevax

0.5 mL dose, given at 0 months.

Trial Locations (36)

15140

Lahti Vaccine Research Clinic, Lahti

20520

Turku Vaccine Research Clinic, Turku

23566

Dr. med. Sobhi Mahdi Kinderarzt und Jugendmedizin, Lübeck

28100

Pori Vaccine Research Clinic, Pori

33014

Tampereen Yliopisto University Of Tampere, Tampere

33100

Tampere Vaccine Research Clinic, Tampere

34225

Gerhard Bleckmann Kinder- und Jugendarzt, Baunatal

34246

Thomas Lenz & (Frau) Dr. med. Marin Eggers, Vellmar

49565

Kinderarzt-Praxis, Bramsche

55131

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz

55566

Gemeinschaftspraxis Dr. med. Guido Hein, Dr. med. Rainer Lauf, Bad Sobernheim

60100

Seinäjoki Vaccine Research Clinic, Seinäjoki

67100

Kokkola Vaccine Research Clinic, Kokkola

73642

Gemeinschaftspraxis fuer Kinder und Jugendliche Welzheim, Welzheim

74523

Dr. Michael Vomstein, Hermann Oesterle, Kinder- und Jugendaerzte, Schwäbisch Hall

77694

Gemeinschaftspraxis fuer Kinder- und Jugendmedizin Dres. Behre, Burgert, Gunkel, Kehl

82362

Dres.T. Schmitz, H. Knee, Ch, Wittermann Fachaerztliche, Weilheim

90220

Oulu Vaccine Research Clinic, Oulu

02100

Espoo Vaccine Research Clinic, Espoo

00100

Helsinki South Vaccine Research Clinic, Helsinki

00930

Ita-Helsinki Vaccine Research Clinic, Helsinki

04400

Järvenpää Vaccine Research Clinic, Järvenpää

FIN-33014

Vaccine Research Center, Tampere

01300

Vantaa Vaccine Research Clinic, Vantaa

39-200

Gabinet Lekarski, Dębica

31-202

Krakowski Szpital Specjalistyczny, im. Jana Pawla II, Krakow

91-347

Specjalistyczna Praktyka Lekarska Gravita, Lodz

21-100

Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Oddzial Pediatryczny, Lubartów

20-044

NZOZ Praktyka Lekarza Rodzinnego Eskulap, Lublin

55-120

NZOZ Praktyka Lekarza Rodzinnego Alina Grocka-Wlazlak, Oborniki Śląskie

61-825

Specjalistyczny ZOZ nad Matka i Dzieckiem, Przychodnia Wieku Rozwojowego, Poznan

41-103

NZLA Michalkowice Jarosz i Partnerzy, Siemianowice Śląskie

87-100

NZOZ Nasz Lekarz, Torun

55-100

Szpital im. Sw. Jadwigi Slaskiej, Oddzial Pediatryczny, Trzebnica

50-345

Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu, Wroclaw

21-010

NZOZ Salmed, Łęczna

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01323270 - A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years. | Biotech Hunter | Biotech Hunter